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Abstract
Phosphorylated residues occur preferentially in the intrinsically disordered regions of eukaryotic 
proteins. In the disordered N-terminal region of human α-actinin-4 (ACTN4), Tyr4 and Tyr31 are 
phosphorylated in cells stimulated with epidermal growth factor (EGF), and a mutant with 
phosphorylation-mimicking mutations of both tyrosines exhibits reduced interaction with actin in 
vitro. Cleavage of ACTN4 by m-calpain, a protease that in motile cells is predominantly activated 
at the rear, removes the Tyr4 site. Here, we found that introducing a phosphomimetic mutation at 
only Tyr31 was sufficient to inhibit the interaction with actin in vitro. However, molecular 
dynamics simulations predicted that Tyr31 is mostly buried and that phosphorylation of Tyr4 
would increase the solvent exposure and thus kinase accessibility of Tyr31. In fibroblast cells, EGF 
stimulation increased tyrosine phosphorylation of a mutant form of ACTN4 with a 
phosphorylation-mimicking residue at Tyr4, whereas a truncation mutant representing the product 
of m-calpain cleavage exhibited EGF-stimulated tyrosine phosphorylation at the background 
amount similar to that observed for a double phosphomimetic mutant of Tyr4 and Tyr31. We also 
found that inhibition of the receptor tyrosine kinases of the TAM family, such as AXL, blocked 
EGF-stimulated tyrosine phosphorylation of ACTN4. Mathematical modeling predicted that the 
kinetics of phosphorylation at Tyr31 can be dictated by the kinase affinity for Tyr4. This study 
suggests that tandem-site phosphorylation within intrinsically disordered regions provides a 
mechanism for a site to function as a switch to reveal a nearby function-regulating site.
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INTRODUCTION
Phosphorylation is an important and reversible mechanism for the regulation of protein 
function (1). In eukaryotic proteins, phosphorylation sites are found with higher frequency 
in intrinsically disordered regions (IDRs) than in structured regions (2), and frequently there 
are multiple phosphorylation sites within an IDR (3). Because signaling proteins have a 
higher proportion of residues in disordered regions than in other proteins (4–6), an 
understanding of how multiple phosphorylation events within IDRs regulate protein function 
is critical for generating a complete picture of cellular signaling. Here, we report evidence of 
a pair of functionally coupled phosphorylation sites within an IDR: One conserved 
phosphorylation site that modulated protein function was regulated by a “tandem” 
phosphorylation site that controlled the accessibility of the former site to its modifying 
kinase in a switch-like fashion.
The α-actinins (ACTNs) are a highly conserved family of actin-crosslinking proteins that 
play important roles during cellular remodeling of the cytoskeleton (7). The multiple 
spectrin repeats in ACTNs form antiparallel homodimers that crosslink actin filaments (8, 
9). Among the four vertebrate ACTN isoforms, ACTN1 and ACTN4 are present 
ubiquitously in non-muscle cells; whereas ACTN2 and ACTN3 are restricted to myocyte 
lineages (10). In addition to filament crosslinking, ACTNs may bridge the cytoskeletal 
network to the cell membrane with ACTN4 in particular playing a critical role in cell 
motility (11–15).
Epidermal growth factor (EGF) stimulates cell migration. Two tyrosines, (Tyr4 and Tyr31) in 
the disordered N-terminal region of ACTN4 are the main sites phosphorylated in EGF-
stimulated cells (16). In addition, a weaker phosphorylation signal that might include 
phosphorylated Tyr265 in the structured actin-binding domain (ABD) is also detected in 
these cells. Motile cells have defined front and rear (trailing) sides with distinct cytoskeletal 
dynamics (17, 18). The protease m-calpain (also known as CAPN2), for example, is 
predominantly activated at the rear of motile cells (19, 20). We have previously shown that 
m-calpain cleaves the ACTN4 N-terminal region such that the first 13 residues, including 
the Tyr4 phosphorylation site, are removed (21).
Tyrosine phosphorylation within the disordered N-terminal region of the non-muscle ACTN 
isoforms regulates their actin binding activity in vitro (16, 22). Phosphorylation-mimicking 
mutations of ACTN4 at both Tyr4 and Tyr31 show decreased actin binding (16). Similarly, 
phosphorylation of ACTN1 by focal adhesion kinase (FAK) at Tyr12, which is homologous 
to Tyr31 in ACTN4, also decreases actin binding (22). Previously, we suggested that 
phosphorylation of ACTN4 Tyr31 results in a conformational change that latches the two 
calponin homology (CH) domains of the ABD into a closed conformation, thereby inhibiting 
the binding to actin filaments (23). The role of the phosphorylation site at Tyr4 in the 
unstructured N-terminal region of ACTN4 is unknown.
To investigate further the functions of the two phosphorylated tyrosines in the N-terminal 
region of ACTN4, we performed in vitro actin-binding assays, molecular dynamics 
simulations (MDS), and phosphorylation assays in EGF-stimulated cells expressing (i) wild-
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type ACTN4, (ii) phosphorylation-mimicking mutants at Tyr4, Tyr31, or both, or (iii) a 
truncation mutant representing the product of m-calpain cleavage within the N-terminal 
region. These studies indicated that only phosphorylated Tyr31 was required to inhibit actin 
binding in vitro, and that Tyr4 functioned as a switch site the phosphorylation of which was 
necessary to enable the phosphorylation of Tyr31. To determine the kinases that may be 
involved in phosphorylating these residues, we inspected the sequences for potential 
consensus motifs and performed experiments with pharmacological inhibitors of kinases that 
are predicted to phosphorylate those motifs. These experiments suggested that EGF-
stimulated phosphorylation of ACTN4 involved the TAM family of receptor tyrosine 
kinases, such as AXL, a hypothesis we confirmed in cells.
Using mathematical modeling, we also showed that, for tandem phosphorylation sites within 
an IDR, fine-tuning of the kinase affinity to the switch site (for example, Tyr4) or the 
relative amounts of the kinase and phosphatase targeting that site would be sufficient to 
regulate the phosphorylation kinetics of the functional site (for example, Tyr31 that functions 
as an inhibitor of actin binding). Thus, tandem phosphorylation sites within IDRs may 
enable the evolution of functional diversity.
RESULTS
Human ACTN4 Tyr31 is a conserved phosphorylation site
To gain insight into the role of dual phosphorylation of the ACTN4 N-terminal region, we 
constructed a multiple sequence alignment of ACTNs from various species (Fig. 1A). In 
human ACTN1, phosphorylation of Tyr12 is sufficient to reduce binding to actin filaments 
(22). The alignment showed that Tyr31 of human ACTN4 represented the homologous 
residue to ACTN1 Tyr12, suggesting that the phosphorylation of Tyr31 is responsible for the 
observed inhibition in actin binding of ACTN4 upon EGF-induced dual phosphorylation of 
its N-terminal region (16). The alignment also showed that this tyrosine is conserved in all 
ACTN proteins analyzed, which indicates that a similar mechanism for regulating actin 
binding may exist for ACTNs in general. We note that in most of the ACTNs there are other 
tyrosines upstream of the conserved Tyr31, however, only phosphorylation at ACTN4 Tyr4 
has so far been detected in this region (16). The region between the two phosphorylation 
sites in ACTN4 is uniquely characterized by the presence of a hydrophobic linker, whereas 
ACTN1 has a shorter hydrophilic stretch of residues next to Tyr12. The differences in the 
biochemical properties of the intervening amino acids suggests that the ACTN4 N-terminal 
region might adopt a more structurally-compact state than the ACTN1 N-terminal region 
(24, 25).
Phosphorylation-mimicking mutation of human ACTN4 Tyr31 inhibits actin binding
We examined the importance of Tyr31 in regulating the interaction of human ACTN4 with 
actin, using in vitro actin-binding assays with full-length ACTN4 constructs containing the 
phosphorylation-mimicking mutation of glutamic acid at Tyr4, Tyr31, or both (Fig. 1B). We 
found that the Y31E single mutant had a similar decrease in binding as the Y4/31E double 
mutant, whereas the Y4E single mutant exhibited binding similar to that of the wild-type 
ACTN4 (Fig. 1C). These results indicated that of the two N-terminal tyrosines that are 
Travers et al. Page 3
Sci Signal. Author manuscript; available in PMC 2015 August 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
phosphorylated in response to EGF, phosphorylation of Tyr31 is likely functionally 
important for inhibiting the actin binding of ACTN4, similar to the role played by 
phosphorylated Tyr12 in ACTN1. Therefore, we refer to Tyr31 as the “function-regulating 
site.”
Molecular dynamics simulations predict that phosphorylation of human ACTN4 Tyr4 is 
required for Tyr31 phosphorylation
To explore the role of Tyr4 phosphorylation, we performed molecular dynamics simulations 
(MDS) of residues 1 to 57 (with residues 1 to 45 and residues 46 to 57 comprising the N-
terminal region and the first helix of the CH1 domain, respectively) for both wild-type 
ACTN4 and the Y4E phosphomimetic mutant and assessed the solvent-accessible surface 
areas surrounding Tyr4 and Tyr31. Three independent simulations for the wild-type sequence 
predicted that the Tyr4 side chain would be solvent exposed and that the Tyr31 side chain 
would be mostly buried (Fig. 2A) within a molten globule packed by two semistable 
antiparallel helices around Tyr4 and Tyr31. These simulations thus predicted that Tyr4, but 
not Tyr31, would be accessible for phosphorylation in the unphosphorylated protein. 
Simulations for the Y4E phosphomimetic predicted that the additional negative charge 
exposes the Tyr31 side chain to solvent (Fig. 2B) by swapping the molten globule to a 
mostly parallel helical arrangement. These models suggested that prior phosphorylation of 
Tyr4 is needed for the function-regulating Tyr31 to become accessible to its kinase. 
Therefore, we refer to Tyr4 as the “switch site.”
ACTN4 contains an m-calpain cleavage site between residues Tyr13 and Gly14 in the N-
terminal region (21), and cleavage at this site removes the Tyr4 phosphorylation site. 
Simulations of the truncated N-terminal region predicted that Tyr31 would remain buried 
and inaccessible to its kinase (Fig. 2C), because the Tyr31 hydroxyl group was often 
observed to be engaged by a helical region between Pro15 and Ala22 that takes the place of 
the helix around Tyr4 in the full protein.
Whereas tandem phosphorylation of ACTN4 is necessary to regulate its actin binding, 
phosphorylation of Tyr12 alone inhibits actin binding of ACTN1 (22). We also ran 
simulations of the hydrophilic N-terminal region of ACTN1 and, as expected, the Tyr12 side 
chain was predicted to be mostly exposed and kinase-accessible (Fig. 2D); the entire 
ACTN1 N-terminal was predicted to adopt a more extended structure than that predicted for 
the ACTN4 N-terminal.
Phosphorylation of Tyr31 depends on Tyr4 in human ACTN4
To test the prediction that Tyr4 and its phosphorylation was required for Tyr31 
phosphorylation, we expressed wild-type ACTN4 tagged with green fluorescent protein 
(GFP), a GFP-tagged Y4E mutant, and a GFP-tagged truncation mutant lacking the first 13 
residues (14-911, representing the protein that would result from m-calpain cleavage) in 
NR6WT fibroblasts. We then tested for EGF-stimulated phosphorylation with an antibody 
that recognizes phosphotyrosine after immunoprecipitating the proteins with an antibody 
recognizing GFP (Fig. 3A). We found a strong signal likely representing phosphorylation of 
both Tyr4 and Tyr31 in cells expressing wild-type ACTN4, whereas we detected less 
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phosphorylation, likely representing phosphorylation of mostly Tyr31, in cells expressing the 
Y4E mutant (Fig. 3B). Assuming that the phosphotyrosine antibody recognizes these two 
sites equally, these results are consistent with previous observations that indicated Tyr4 as 
the major site of phosphorylation upon EGF stimulation (16).
We also found that the truncated mutant had significantly reduced tyrosine phosphorylation 
compared to either the wild-type or Y4E constructs. These results indicated that Tyr31 
phosphorylation occurred to a much lesser extent when Tyr4 was not present and available 
for phosphorylation. Therefore, we proposed a mechanism by which an initially 
phosphorylated site reshapes the molten globule structure of an IDR and thereby enables 
kinase-accessibility of a nearby function-regulating phosphorylation site (Fig. 3C).
An aspartic acid adjacent to human ACTN4 Tyr4 is important for phosphorylation
One approach to identifying kinases that may phosphorylate Tyr4 and Tyr31 is to inspect the 
sequence surrounding those sites for conserved motifs recognized by specific kinases. We 
noted that the similarity of the sequence motif around human Tyr4 and Tyr31, MXD-pY-XA, 
suggested that a single class of kinases (or even the same kinase) may phosphorylate both 
sites. Hence, we postulated that mutations to either Asp3 or Asp30 would lead to weaker 
kinase affinity for the adjacent Tyr4 or Tyr31, respectively, and decrease overall 
phosphorylation levels relative to that of the wild-type protein. MDS of N-terminal 
constructs containing either D3A or D30A mutations predicted that, contrary to the wild-
type ACTN4 N-terminal region, Tyr31 phosphorylation would be decoupled from Tyr4 
phosphorylation, because Tyr31 was almost equally solvent exposed as in Y4E (Fig. 4A). 
Thus, considering the change in specificity of the binding site due to the aspartic acid 
mutations, we predicted that tyrosine phosphorylation of the D3A mutant in cells would be 
at least as much as that of the Y4E phosphomimetic mutant, because MDS predicted that 
both mutants had solvent-exposed Tyr31. We also predicted that the D30A mutant would 
have at least as much tyrosine phosphorylation in cells as the Y31E phosphomimetic mutant, 
because the switch site (Tyr4) would be exposed and have an unaltered phosphorylation 
consensus motif in both mutant versions of ACTN4.
To test these predictions, we expressed GFP-tagged constructs of human ACTN4 containing 
the single mutations D3A or D30A or the double mutation D3/30A in the fibroblast cell line 
and assayed for tyrosine phosphorylation of the GFP-tagged proteins immunoprecipitated 
from cells that were either exposed to EGF or not (Fig. 4B). In EGF-stimulated cells, the 
D3A mutant exhibited less phosphorylation than wild-type ACTN4 and more than Y4E (Fig. 
4C), indicating that the mutation at Asp3 decreased (but did not completely inhibit) Tyr4 
phosphorylation. EGF-stimulated D30A phosphorylation was not significantly different 
from that of wild-type ACTN4 and was higher than that of the Y31E mutant or D3/30A 
double mutant. These data indicated that the phosphorylation of ACTN4 Tyr4 primarily 
depended on its surrounding sequence.
EGF-induced phosphorylation of ACTN4 is independent of FAK
FAK phosphorylates Tyr12 in the disordered N-terminal region of human ACTN1 (22). 
Because the kinase activity of FAK is inhibited in A431 epidermoid carcinoma cells upon 
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stimulation with EGF (26), we showed that EGF-induced phosphorylation of ACTN4 was 
unaffected by FAK inhibition (Figs. 5A and 5B). Moreover, consistent with the similarity 
between the sequence motif around human ACTN4 Tyr31 (DY31MAQ) and ACTN1 Tyr12 
(DY12MQP), we found that EGF also stimulated tyrosine phosphorylation of GFP-tagged 
ACTN1 in a FAK-independent manner. This result suggested that there are at least two 
pathways by which the ACTN1 N-terminal region is phosphorylated: by FAK (in the 
absence of EGF) and by a FAK-independent pathway that is activated by EGF.
AXL may be involved in dual phosphorylation of the ACTN4 N-terminal region
We scanned for potential kinases of the ACTN4 Tyr4 and Tyr31 sites using PhosphoNET 
(http://www.phosphonet.ca) (27), which indicated that the most likely candidate for both 
sites is the receptor tyrosine kinase AXL. To check for the involvement of AXL, we 
analyzed the amount of tyrosine phosphorylation in GFP-tagged wild-type, Y4E, and Y31E 
ACTN4 constructs in cells that were exposed to EGF and also to various kinase inhibitors. 
As was shown previously (16), inhibition of the EGF receptor or the stress-activated kinase 
p38 blocked EGF-stimulated tyrosine phosphorylation for each of these constructs (Figs. 5C 
and 5D). We also found that R428, an inhibitor of the TAM (TYRO3, AXL, and MER) 
family of receptor tyrosine kinases (28), also reduced tyrosine phosphorylation for each of 
these constructs. Thus, EGF may stimulate a pathway that involves the kinase p38 and TAM 
family members, but does not involve FAK, to trigger the tyrosine phosphorylation of the 
ACTN4 N-terminal and thus inhibit the interaction of ACTN4 with actin.
Switch-like changes in Tyr31 phosphorylation can arise by fine-tuning the kinase affinity 
for the Tyr4 site
Integrating the signals arising from multiple phosphorylation and dephosphorylation events 
leads to complex nonlinear responses, which can be explored using mathematical modeling 
(29, 30). Previous findings from models of multisite sequential phosphorylation (31–33) do 
not apply to our tandem phosphorylation model for ACTN4, because here the actin-binding 
inhibited state only requires phosphorylation of one of the paired sites, Tyr31. Hence, to 
understand the constraints imposed by the switch site at Tyr4 on the phosphorylation of the 
“function-regulating site” at Tyr31, we used a mathematical modeling approach (see 
Methods) to compare the steady-state proportion of phosphorylation on the function-
regulating site in a single-site model (for example, at the single Tyr12 site in ACTN1) and in 
a two-site tandem model undergoing sequential phosphorylation (for example, in ACTN4). 
We solved these models assuming that a single kinase and a single phosphatase act on the 
phosphorylation sites and that the catalytic rates of the kinase and phosphatase are the same. 
Note that we follow here the notation of Rowland et al. (30), with the Michaelis constant for 
the kinase acting on Tyr4 denoted as KM,KY4 (and similar notation for the other constants).
For the single-site model (Fig. 6A), which is also referred to as the Goldbeter-Koshland loop 
(34), phosphorylation of the function-regulating site increased hyperbolically with the ratio 
of the activities (taken here to be proportional to the concentrations) of kinase to 
phosphatase at nonsaturating conditions of the substrate. However, at saturating 
concentrations the system shows an ultrasensitive switch-like behavior such that the amount 
of phosphorylated substrate abruptly shifts as the ratio of kinase to phosphatase activity 
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changes: Maximally-phosphorylated Tyr12 already occurs once the kinase activity becomes 
slightly greater than the phosphatase activity, and shifts to minimally-phosphorylated Tyr12 
once phosphatase activity becomes slightly greater than kinase activity.
For the two-site tandem model, we found that when the relative affinity of the kinase for the 
switch site (Tyr4 of ACTN4) was lowered by 50-fold compared to the affinity for the 
function-regulating site (Tyr31 in ACTN4), phosphorylation of the latter site was 
dramatically lower unless ACTN4 was present at saturating concentrations and there was 
around twice as much kinase activity to phosphatase activity (Fig. 6B). For unsaturated 
conditions, maximum phosphorylation resulted from a hyperbolic (instead of a switch-like) 
response only upon reaching a large enough kinase to phosphatase activity ratio. A similar 
type of behavior is for single-site systems in which the kinase and phosphatase can be 
treated as unsaturated and saturated, respectively (35). However, if the kinase is set to have 
similar affinities for both sites, the phosphorylation kinetics of the function-regulating site 
exhibited switch-like behavior similar to the single-site model for substrate concentrations 
ten times or more larger than the kinase Michaelis constant of the kinase for both sites (Fig. 
6C, black curve; note that KM,KY31 is equal to KM,KY4 in this plot).
Moreover, our analysis revealed that as long as the kinase affinity towards the switch site is 
higher than its affinity towards the function-regulating site (KM,KY4 ≤ KM,KY31), a switch-
like phosphorylation response with respect to the ratio of kinase to phosphatase activities is 
always observed (Fig. 6D). This is consistent with Tyr4 and Tyr31 serving as major and 
minor sites of phosphorylation, respectively (16) (Figs. 4C and 5D). Note that quantitatively, 
the results in Fig. 6D are identical to that for a two-kinase, one-phosphatase model system in 
which the two kinases (denoted K1 and K2) would have the same concentration but varying 
affinities for their corresponding site (with KM,K1Y31/KM,K2Y4 in one of the axes in Fig. 
6D). In this theoretical two-kinase, one-phosphatase model, a switch-like response would 
occur if KM,K2Y4 < KM,K1Y31 and a low level response would occur if KM,K2Y4 > 
KM,K1Y31. From an evolutionary point of view, we note that in order for the tandem 
phosphorylation site Tyr4 to efficiently work as a toggle for Tyr31 phosphorylation, it is 
sufficient to evolve the appropriate kinase affinity to the Tyr4 site (KM,KY4), while leaving 
the parameters related to the Tyr31 site unchanged.
DISCUSSION
By functioning as molecular switches, posttranslational modifications can mediate diverse 
signaling pathways. Using insights from MDS and mathematical modeling, our findings 
provide a framework for understanding a previously uncharacterized molecular switch that 
facilitates context-dependent regulation. On the basis of sequence similarity with other 
ACTN isoforms and in vitro actin-binding results, we concluded that phosphorylation of 
Tyr31 inhibits actin binding, likely by latching both CH domains in a closed conformation 
(23). MDS predicted that in the N-terminal region of wild-type ACTN4, Tyr4 and Tyr31 are 
mostly accessible and inaccessible, respectively, for phosphorylation and that Tyr4 
phosphorylation leads to structural changes in the IDR that exposes Tyr31 to make it kinase 
accessible. Thus, we proposed that the phosphorylation state of Tyr4 acts as a switch that 
determines whether the function-regulating site Tyr31 can become phosphorylated.
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By utilizing a second phosphorylation site 27 residues away from the function-regulating 
site in the intrinsically disordered N-terminal region of ACTN4, the cell may differentially 
regulate actin crosslinking through the locale-specific presence of m-calpain and locale-
specific activation of the kinases that phosphorylate the tandem sites. Our modeling also 
indicated that by adding a switch site, optimizing the phosphorylation of a nearby functional 
site within an IDR can be achieved simply by fine-tuning the kinase affinity of the switch 
relative to that of the functional site. We note that developing a tandem phosphorylation 
mechanism within a structured protein region to control the solvent exposure of a function-
regulating site would be more complicated, and, for example, entail evolving an entire 
phosphorylatable binding partner, either as another protein or as a separate domain in the 
same protein, which can reversibly bind and cover this site Thus, the evolution of tandem 
phosphorylation sites within IDRs poses advantages relative to their evolution within 
structured domains, which is also consistent with the higher mutation rates observed in IDRs 
(36).
Our results indicate that cytoplasmic FAK involvement is not necessary for EGF-induced 
tyrosine phosphorylation of ACTN4 and ACTN1. We instead found that AXL or other TAM 
family members may be involved in the EGF-stimulated tyrosine phosphorylation of 
ACTN4. Expression of both AXL and ACTN4 is increased in cells from invasive endometrial 
tissue of patients with endometriosis (37), which may be a precursor of ovarian cancer (38). 
In addition, AXL can be transactivated by the EGF receptor (39). AXL has also been 
implicated in reorganization of the actin cytoskeleton and migration of neuronal cells, with 
activation of p38 occurring downstream of AXL (40, 41). Pending further investigation of 
the role of p38 in fibroblast cell migration, receptor tyrosine kinase-mediated 
phosphorylation of Tyr4 and Tyr31 is consistent with the predominant localization of 
ACTN4 at the cytosolic side of the plasma membrane to participate in actin cytoskeleton 
remodeling (42, 43).
In addition to dual phosphorylation of Tyr4 and Tyr31 in the disordered N-terminal region of 
ACTN4, EGF also stimulates a less easily detected phosphorylation of ACTN4 that may 
include phosphorylation of Tyr265, which is located in the ABD (16). Therefore, we interpret 
the tyrosine phosphorylation detected in cells expressing the Y4E mutant as primarily 
resulting from phosphorylation of Tyr31 and that in cells expressing the Y31E mutant as 
representing phosphorylation of Tyr4.
We propose that tandem phosphorylation of the ACTN4 N-terminal region provides a 
rationale for locale-specific adhesion contacts during cell motility mediated by m-calpain, 
which is activated only at the rear of motile cells (19, 20). Namely, at the same time that the 
leading edge of the cell protrudes and makes new adhesion contacts with the outside matrix, 
the rear of the cell has to remain stably attached to the matrix through its own adhesion 
contacts. Hence, by cleaving the ACTN4 N-terminal region such that Tyr31 is no longer 
accessible for phosphorylation, even in the presence of EGF at the rear end of motile cells 
(44), m-calpain would stabilize the crosslinks between ACTN4 and F-actin to the cell 
membrane at the cell rear (21). Subsequently, m-calpain cleavage of talin loosens linkages 
between the actin cytoskeleton and adhesion plaques (45) to enable the cell body to move 
forward with the cell membrane. At the leading edge where m-calpain is not present, EGF-
Travers et al. Page 8
Sci Signal. Author manuscript; available in PMC 2015 August 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
induced tandem phosphorylation of the ACTN4 N-terminal region reduces actin binding, 
enabling dynamic restructuring of the actin network so that the leading edge extends forward 
and forms new contacts. In our model, tandem phosphorylation of ACTN4 in conjunction 
with m-calpain leads to locale-specific ACTN4 function such that at the front end EGF 
induces reduction of actin binding, while at the rear m-calpain cleavage stabilizes the 
ACTN4-actin interaction. We note that the m-calpain cleavage site is not conserved in the 
other three vertebrate ACTN isoforms (Fig. 1). The conservation of both the cleavage and 
tandem phosphorylation sites only in vertebrate ACTN4 suggests that tandem 
phosphorylation in ACTN4 co-evolved with a mechanism by which the Tyr4 switch can be 
permanently turned off, disabling the main regulatory pathway that inhibits actin binding by 
ACTN4.
We anticipate that many other systems could exhibit a similar tandem —switch site and 
function-regulating site— mechanism of regulation and that this type of regulation could 
involve multiple kinases. Other systems with similar designs have been described. For 
instance, structural analysis of two tyrosine phosphorylation sites that are separated by 34 
residues in the cytoplasmic domain of LRP1 (low density lipoprotein receptor-related 
protein) showed that the Tyr4507 site in the membrane-distal NPXY motif is fully solvent-
exposed, while the Tyr4473 site in the membrane-proximal NPXY motif is initially buried 
but has increased solvent exposure and kinase accessibility upon phosphorylation at Tyr4507 
(46). Analogous to the roles of Tyr31 and Tyr4 in ACTN4, Tyr4473 phosphorylation is the 
functional site that inhibits binding to Snx17 (sorting nexin 17), and phosphorylation of only 
the Tyr4507 switch did not impact this binding (46). Another system with potential tandem 
phosphorylation sites is the C-terminal region of STAT1 (signal transducer and activator of 
transcription 1) that has two phosphorylation sites, Tyr701 and Ser727, which are separated 
by 26 residues and for which Ser727 phosphorylation depends on prior phosphorylation of 
Tyr701 in response to interferons (47). The observation that IDRs have a higher propensity 
for phosphorylation sites suggests that tandem phosphorylation within IDRs is another 
mechanism to regulate protein function.
MATERIALS AND METHODS
Multiple sequence alignment and phylogenetic tree construction
ACTN protein sequences from various species were obtained from the NCBI protein 
database. Multiple sequence alignment and phylogenetic tree construction for these 
sequences were done using the interface provided by the Phylogeny.fr web service (48). The 
alignment was constructed with MUSCLE (49), using default parameters provided by the 
web service. The maximum likelihood phylogenetic tree was then constructed from this 
alignment using PhyML (50), also using default parameters provided by the web service. 
Statistical support for the tree branches was computed by bootstrapping with 100 replicates. 
TreeDyn (51) was used for rendering the phylogenetic tree.
Molecular dynamics simulations
All MDS used explicit solvent and were performed with the GPU-accelerated pmemd.cuda 
program from Amber version 14 (52, 53) using the Amber ff14SB force field. The starting 
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conformation for the ACTN4 wild-type N-terminal region was taken from an earlier 
implicit-solvent MDS, which started from a fully-extended conformation of residues 1 to 45 
and showed burying of Tyr31 (23). This conformation was attached to a helical segment 
comprising residues 46 to 57 from the first helix of the structured CH1 domain. The C-
terminus of this entire construct was neutralized using an N-methylamide (NME) patch. To 
get the starting conformations for the various ACTN4 mutant sequences, point mutations 
(Y4E, D3A, D30A) and truncations (removal of residues 1 to 13 to model m-calpain 
cleavage) were then done using PyMOL (54). Similarly, to get the starting conformation for 
the ACTN1 wild-type N-terminal region, point mutations and truncations were done such 
that the structure around the conserved tyrosine phosphorylation site (Tyr31 or Tyr12 in 
ACTN4 or ACTN1, respectively) remained intact. All systems were solvated with TIP3P 
water molecules (55) in an octahedral box, and counter ions were added to neutralize the 
system charge. A cutoff of 8.0 Å was used for calculating short-range Lennard-Jones and 
electrostatic interactions, and long-range electrostatic contributions were computed using the 
particle mesh Ewald approach (56). An AMBER implementation of the hydrogen mass 
repartitioning scheme (57) allowed a time step of 4 fs to be used. All bond lengths involving 
hydrogen were kept constant using SHAKE (or SETTLE for water) (58, 59). Initial energy 
minimization was performed using steepest descent for 1000 steps then conjugate gradient 
minimization for 1000 steps. This was followed by temperature equilibration at 300 K for 50 
ps under canonical (conserved number of particles [N], volume [V], and temperature [T]; or 
NVT) ensemble conditions, and then pressure equilibration at 1 atm and 300 K for another 
50 ps under isothermal-isobaric (conserved number of particles [N], pressure [P], and 
temperature [T]; or NPT) ensemble conditions. All heavy atoms had position restraints up to 
this point. This was followed by further equilibration for 100 ns and then a production run 
for 500 ns, all under NVT ensemble conditions at 300 K and with position restraints on only 
the backbone heavy atoms comprising the helical segment from CH1. All MDS were done 
with triplicate runs, for a total sampling time of 1.5 µs. VMD (60) was used for trajectory 
visualization and SASA computations. Moving averages at every nanosecond were 
computed and plotted for the relative SASA.
Rule-based mathematical modeling simulations
Reaction rules to describe the single-site model and the 1-kinase/1-phosphatase (1K1P) two-
site tandem model were implemented using BioNetGen v2.2.5 (61), which generates a 
complete set of ordinary differential equations (ODEs) for these models. The ODEs were 
then numerically integrated using the CVODE interface provided by BioNetGen until 
steady-state levels were reached. Details on the reaction rules and parameter values used for 
these models are provided in the Supplementary Notes.
ACTN4 constructs and experimental assays
Expression of wild-type ACTN4 and ACTN1 and various mutant ACTN4 constructs (Y4E, 
Y31E, Y4/31E, D3A, D30A, D3/30A, and truncation mutant 14-911), F-actin sedimentation 
SUPPLEMENTARY MATERIALS
Supplementary Notes. Reaction Rules and Parameter Values for the Simulations of Single-Site and Two-Site Tandem 
Phosphorylation Models.
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assays, and phosphorylation assays were all performed as described previously (16, 21). In 
brief, all ACTN4 mutagenesis was performed using PCR followed by DNA sequencing 
analysis to confirm mutations. Wild-type and mutant ACTN4, and wild-type ACTN1, 
constructs were then cloned into vector pET-28a for expression in bacterial cells and 
pEGFP-N1 for expression in mammalian cells. For actin-binding assays, 10 µg ACTN4 that 
was purified from bacteria was incubated with 20 µg actin (Sigma) in actin-binding buffer 
(10 mM Tris-HCl pH 7.4, 2mM MgCl2, 120 mM NaCl, 0.5 mM ATP, and 0.5 mM EDTA) 
at room temperature for 1 hour followed by centrifugation at 100,000g for 40 minutes. 
Supernatant was collected and the pellet was briefly and carefully rinsed with water and 
dissolved in 2× Laemmli sample buffer. After boiling for 4 minutes, proteins were run on 
SDS-PAGE followed by Coomassie staining.
For phosphorylation assays, NR6WT fibroblast cells that had been transiently transfected 
with ACTN4 or ACTN1 plasmids using Lipofectamine 2000 (Life Technologies, catalog # 
11668019) according to the manufacturer’s instructions were starved with quiescence 
medium (α-MEM [catalog no. 15-012-CV; Cellgro, Lawrence KS] with 0.1% dialyzed fetal 
bovine serum, 1× nonessential amino acids, 1× sodium pyruvate, 1× streptomycin/penicillin, 
and 2 mM L-glutamine) for 18 hours and then pretreated with appropriate inhibitors [10 µM 
FAK inhibitor II (EMD Millipore, Calbiochem, catalog # 324878); 10 µM EGFR inhibitor 
PD153035 (EMD Millipore, Calbiochem, catalog # 234490-1MG); 15 µM p38 inhibitor 
SB203580 (EMD Milllipore, Calbiochem, catalog # 19-135); or 15 µM TAM inhibitor R428 
(ApexBio, catalog # A8329)] for 30 minutes prior to treatment with 10 nM EGF for 1 hour. 
Cells were then harvested and lysed, and GFP-tagged protein was immunoprecipitated with 
monoclonal GFP antibody (Life Technology, Catalog # A-11120) followed by SDS-PAGE 
and immunoblotting against phosphorylated Tyr (Cell signaling Technology, catalog # 
9411). After immunoblotting, the PVDF membrane was stripped of antibodies and stained 
with Coomassie blue G-250 to detect the amount of ACTN4-eGFP protein. This approach 
was further validated by immunodetection of ACTN4 or the GFP tag. Quantitative analysis 
was performed using ImageJ software (62).
Statistical analysis
Plotted experimental data are shown as mean values ± SEM. Two-sided Student’s t test was 
used for comparison of sample means. P < 0.05 was considered to be statistically significant. 
All statistical analysis were performed in Microsoft Excel version 2013.
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Figure 1. Phosphorylation of Tyr31 in ACTN4 is necessary and sufficient to inhibit actin binding
(A) Multiple sequence alignment (right) and phylogenetic tree (left) of ACTN isoforms from 
various animal species. Only the disordered N-terminal regions are shown in the alignment. 
The column colored in red contains the highly conserved Tyr31 from human ACTN4 
(HOMO_4), which is homologous to Tyr12 in human ACTN1 (HOMO_1). Columns 
containing the Tyr4 sites of ACTN4 and ACTN1 are colored in blue and green, respectively. 
Note that the ACTN4 sequences are characterized by the insertion of a hydrophobic linker 
between Tyr4 and Tyr31. Numbers to the right of branch points in the phylogenetic tree 
represent bootstrap support based on 100 replicates. Branches within the ACTN1-4 clusters 
all have bootstrap support values of at least 0.98. Scale bar represents the number of 
substitutions per site. (B) Representative gel of actin-binding assay for WT, Y4E, Y31E, and 
Y4/31E constructs of ACTN4, following ultracentrifugation and separation of supernatant 
(S) and pellet (P). (C) Quantitation of three actin-binding experiments for the fraction of 
bound ACTN4 in the pellet. Error bars indicate SEM. [* P < 0.05 based on two-sided 
Student’s t-test. NS, not significant.] The asterisk applies to the following four pairwise 
comparisons: WT vs. Y31E, WT vs. Y4/31E, Y4E vs. Y31E, and Y4E vs. Y4/31E.
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Figure 2. MDS predict that ACTN4 Tyr31 is kinase inaccessible without phosphorylated Tyr4
Three independent MDS were performed for N-terminal constructs of wild-type ACTN4, 
Y4E ACTN4, truncated ACTN4, and wild-type ACTN1. In each panel, a representative 
relative solvent-accessible surface area (SASA) plot (top) and structure snapshot (bottom) 
are shown. Snapshots are displayed with rainbow coloring from dark blue to red in the N-to-
C direction. (A) Tyr4 and Tyr31 (dark blue and yellow spheres) were mostly solvent exposed 
and buried (relative SASA: 71 ± 9% and 11 ± 8%), respectively. Two helices adopted an 
antiparallel arrangement that buried Tyr31. The primary m-calpain cleavage site (Tyr13-
Gly14 peptide bond; red arrow) was exposed. (B) Tyr31 is mostly solvent exposed (relative 
SASA: 64 ± 13%) because the additional negative charge flipped the helices into a parallel 
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arrangement. (C) Removal of residues 1 to 13 led to a mostly helical region between Pro15 
to Ala22 and kept Tyr31 buried (relative SASA: 17 ± 8%). (D) ACTN1 was more extended 
due to its hydrophilic sequence, and Tyr12 (green spheres) was mostly solvent exposed 
(relative SASA: 73 ± 12%). Relative SASA values are given as mean ± SD over the three 
MDS runs.
Travers et al. Page 17
Sci Signal. Author manuscript; available in PMC 2015 August 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Figure 3. Tyr31 phosphorylation in ACTN4 requires prior phosphorylation at Tyr4
(A) Representative gel of phosphorylation detection assay for wild-type (WT), Y4E, and 
14-911 ACTN4-GFP constructs in the presence (+) or absence (−) of EGF. IP:GFP, 
immunoprecipitation with an antibody recognizing GFP; IB:pY, immunoblot with an 
antibody recognizing phosphorylated tyrosines. Total ACTN4-eGFP was detected with 
Coomassie blue G-250. (B) Quantitation of three experiments for the ratio of density units 
between phosphorylated tyrosine band over total protein band for each ACTN4 construct. 
Error bars indicate SEM. [* P < 0.05, two-sided Student’s t-test.] (C) Tandem 
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phosphorylation model for the ACTN4 disordered N-terminal region. (i) Tyr4 and Tyr31 are 
initially accessible and inaccessible, respectively, for phosphorylation (Pi), and Tyr4 gets 
phosphorylated (pY4). (ii) Phosphorylation of Tyr4 triggers structural changes in the 
disordered N-terminal region that lead to the exposure of Tyr31 and its phosphorylation 
(pY31). (iii) Phosphorylated Tyr31 inhibits binding of ACTN4 to actin by latching the two 
CH domains of the ABD in a closed configuration. Wavy lines in the N-terminal region 
denote alpha-helical structures. Red arrow indicates the m-calpain cleavage site between 
Tyr13-Gly14.
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Figure 4. Phosphorylation of ACTN4 Tyr4 is decreased upon mutation of the adjacent Asp3
(A) Representative plots (for one out of three independent MDS) showing relative SASA of 
Tyr4 and Tyr31 from D3A (top) and D30A (bottom) ACTN4 constructs. These mutations 
lead to both Tyr4 and Tyr31 being mostly solvent exposed (relative SASA of Tyr4 and Tyr31: 
67 ± 14% and 66 ± 14% for D3A, 66 ± 12% and 64 ± 9% for D30A). Relative SASA values 
are given as mean ± SD over the three runs. (B) Representative gel of phosphorylation 
detection assay for wild-type (WT), D3A, D30A, D3/30A, Y4E, Y31E, and Y4/31E 
ACTN4-GFP constructs in the presence (+) or absence (−) of EGF. IP:GFP, 
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immunoprecipitation with an antibody recognizing GFP; IB:pY, immunoblot with an 
antibody recognizing phosphorylated tyrosines. Total ACTN4-eGFP protein was detected 
with Coomassie blue G-250. (C) Quantitation of three experiments for the ratio of density 
units between phosphorylated tyrosine band over total protein band for each ACTN4 
construct. Error bars indicate SEM. [* P < 0.05 based on two-sided Student’s t-test. NS, not 
significant.]
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Figure 5. TAM family members, but not FAK, may be involved in EGF-induced 
phosphorylation of ACTN4
(A) Representative gel of EGF-induced phosphorylation detection assay for ACTN4-GFP 
and ACTN1-GFP in the presence (+) or absence (−) of 10 µM FAK inhibitor II. (B) 
Quantitation of three experiments for the ratio of density units between phosphorylated 
tyrosine band over total protein band for ACTN4 or ACTN1. Error bars indicate SEM. [NS, 
not significant.] (C) Representative gel of phosphorylation detection assay for wild-type 
(WT), Y4E, and Y31E ACTN4-GFP constructs in the presence of EGF alone or with one of 
the following: 10 µM EGFR inhibitor (PD153035), 15 µM p38 inhibitor (SB203580), or 15 
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µM TAM inhibitor (R428). (D) Quantitation of three experiments for the ratio of density 
units between phosphorylated tyrosine band over total protein band for each ACTN4 
construct. Error bars indicate SEM. [* P < 0.05 based on two-sided Student’s t-test.] 
IP:GFP, immunoprecipitation with an antibody recognizing GFP; IB:pY, immunoblot with 
an antibody recognizing phosphorylated tyrosines. Total ACTN4-eGFP protein was detected 
by staining with Coomassie blue G-250.
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Figure 6. Tuning the kinase affinity of Tyr4 is enough to design a switch
(A) Modeling results for phosphorylation in a single-site model (such as in ACTN1). 
Fraction of phosphorylated site is plotted against the ratio of kinase/phosphatase 
concentrations ([Kin]/[Pho]) and total ACTN1 concentration normalized by the kinase KM 
; plotted as log scale). The KM of the kinase and phosphatase for the site 
are set equal. (B) Results for phosphorylation of the functional site in a 1-kinase/1-
phosphatase (1K1P) two-site tandem model (such as in ACTN4), where the kinase has a 50-
fold weaker affinity for the switch site  than the functional site . Axes are 
similar as in (A). (C) Results for same model as in (B), but where the kinase has the same 
KM,K for both sites. Black curve shows the amount of phosphorylated Tyr31 as a function of 
[Kin]/[Pho] when . (D) Results for the 1K1P two-site tandem model 
where the fraction of phosphorylated site is plotted against [Kin]/[Pho] and the kinase KM 
ratio for both sites , with . Black curve shows the amount 
of phosphorylated Tyr31 as a function of [Kin]/[Pho] when . All enzyme 
concentrations are assumed to be directly proportional to their activities.
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